Jack Nathan Health Announces Its Q4 and Year End Fiscal 2025 Financial Results
-
MedSpa revenues grew
90% year-over-year -
Net income from discontinued operations of
due to gain on sale of Canadian Primary Care and Licensee business$9.99 million -
Mexico operations fully ceased as of June 30, 2025
Disclosure Regarding Filing Timing
As previously disclosed in a press release issued on June 9, 2025, the Company was unable to file its annual financial statements, MD&A, and related CEO and CFO certifications for the fiscal year ended January 31, 2025, by the prescribed filing deadline of May 31, 2025. The delay was due to operational restructuring, resource realignment, and transition impacts following the divestiture of its Canadian primary care operations and the winding down of
Management Commentary
Mike Marchelletta, Chief Executive Officer, commented:
“Fiscal 2025 was a pivotal year of transition for Jack Nathan Health. We successfully completed the divestiture of our Canadian primary care and licensee business, which significantly improved our balance sheet and eliminated legacy obligations. Following year-end, we also ceased all clinic operations in
Financial Highlights for the fiscal year ended January 31, 2025
Operating Results |
|||||
2025 |
2024 |
2023 |
|||
$ | $ | ||||
Revenues (Continuing + Discontinued) | 19,146,626 |
19,144,923 |
15,487,698 |
||
Net loss from continuing operations | (2,530,374) |
(1,333,217) |
(6,902,759) |
||
Net Income/(loss) from discontinued operations | 9,995,129 |
(5,302,750) |
- |
||
Total comprehensive income/ (loss) | 7,678,435 |
(6,737,300) |
(7,077,020) |
For the fiscal year ended January 31, 2025, total consolidated revenues were
Note on Mexico Operations:
The 2025 financial statements reflect the
The Company reported a loss from continuing operations of
Balance Sheet as of January 31, 2025
-
Cash of
(January 31, 2024 -$2.2 million )$3.06 million -
Total assets of
(January 31, 2024 -$3.54 million )$11.19 million -
Total liabilities of
(January 31, 2024 -$2.22 million )$17.13 million
Working capital improved to
Shares Outstanding
As of January 31, 2025, the Company had 87,099,159 common shares outstanding, 1,650,000 stock options outstanding and 335,004 DSUs outstanding.
For further information regarding the Company’s financial results for fiscal year ended January 31, 2025, please refer to the audited annual consolidated financial statements of the Company as at and for the 12 months ended January 31, 2025 together with the corresponding MD&A, available at and the JNH website https//investor.jnhmexico.com
About Jack Nathan Medical Corp.
Jack Nathan Health® is a provider of MedSpa services in
For more information, visit https//investor.jnhmexico.com or
Neither the TSX Venture Exchange nor its Regulation Services Provider (as defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Appendix:
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to Jack Nathan are intended to identify forward- looking information. All statements other than statements of historical fact may be forward- looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to them, and are subject to certain risks, uncertainties, and assumptions Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative and other judicial, regulatory, political, and competitive developments; and operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward- looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward- looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward- looking information, other than as required by applicable law.
View source version on businesswire.com:
Jack Nathan Medical Corp., Mike Marchelletta, Chief Executive Officer, (647)-488-5008
Source: Jack Nathan Medical Corp.